Tests telisotuzumab adizutecan with bevacizumab in colorectal cancer that stopped responding
Compares a new drug with bevacizumab against standard treatment in adults with colorectal cancer.
Key facts
- Who runs it
- AbbVie
- Where
- Busan, Hwasun-gun, Incheon, Seongnam, Seoul, and Suwon, South KoreaSee the 7 sitesAlso in 9 other countries, 87 sites
- Trial code
- Registry title
- A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 990 people, planned
- Started
- 22 May 2026
- Expected to end
- Mar 2030
- Type of study
- Interventional, 2 groups
- Treatments tested
- Telisotuzumab adizutecan
- Bevacizumab
- Trifluridine/Tipiracil
- Record updated
- 19 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with colorectal cancer that has spread and has not responded to earlier treatment. They would get telisotuzumab adizutecan with bevacizumab, or the standard treatment trifluridine/tipiracil (LONSURF) with bevacizumab.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Refractory metastatic colorectal cancer (cancer that has spread and has not responded to earlier treatment).
- Earlier treatment
- People who had a treatment targeting c-Met, or an antibody drug conjugate that blocks Top-1, cannot join.
Main reasons for not taking part
- Earlier treatment with a c-Met targeting drug or a Top-1 inhibitor antibody drug conjugate
- Past allergy or intolerance to bevacizumab or similar drugs to trifluridine/tipiracil
- Past allergy to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies
- Drug or alcohol abuse within the last 6 months
- Life expectancy shorter than 12 weeks
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Must voluntarily sign and date an informed consent, approved by an Ethics Committee (IEC)/ Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures. Participants must have the capacity to consent in the opinion of the investigator
- Life expectancy >= 12 weeks per investigator assessment
Who cannot take part
- Prior systemic regimen containing c-Met targeting agent (e.g., antibody, antibody drug conjugate, bispecific) or any Top-1 inhibitor ADC
- History of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies
- History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months
- History of intolerance, allergic reactions or hypersensitivity to bevacizumab or any of its excipients, or to compounds similar to trifluridine/tipiracil. This also includes patients with known rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
Where in South Korea
Also in 9 other countries, 87 sites
- Dong-A University Medical CenterBusan, South KoreaTaking people
- Chonnam National University Hwasun HospitalHwasun-gun, South KoreaTaking people
- Gachon University Gil Medical CenterIncheon, South KoreaTaking people
- CHA Bundang Medical CenterSeongnam, South KoreaTaking people
- Asan Medical CenterSeoul, South KoreaTaking people
- Seoul National University HospitalSeoul, South KoreaTaking people
- The Catholic University Of Korea St. Vincent's HospitalSuwon, South KoreaTaking people
About the trial
What the trial wants to find out
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine and tipiracil) plus bevacizumab in adult participants with refractory metastatic colorectal cancer (mCRC).
Read full original descriptionShow less
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants will then be randomized into 2 groups called treatment arms. One group will receive telisotuzumab adizutecan with bevacizumab in different doses. Another group will receive standard of care (SOC), trifluridine and tipiracil (LONSURF), with Bevacizumab. Up to approximately 990 adult participants with refractory mCRC, will be enrolled in the study in approximately 125 sites globally.
In this Phase 3, one of two groups will receive doses of Intravenous (IV) telisotuzumab adizutecan + bevacizumab and other group will receive oral SOC of trifluridine/tipiracil (LONSURF)+ Intravenous (IV) bevacizumab. The study will run for a duration of approximately of 36 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
The 2 groups in the trial
- Ph 3: Telisotuzumab Adizutecan + BevacizumabTreatment being tested
Participants will receive telisotuzumab adizutecan + Bevacizumab as part of an approximately 36 months study duration.
Treatment: Telisotuzumab adizutecan and Bevacizumab
- Ph 3: SOC Trifluridine and Tipiracil + BevacizumabTreatment being tested
Participants will receive standard of care (SOC) trifluridine and tipiracil +Bevacizumab as part of an an approximately 36 months study duration.
Treatment: Bevacizumab and Trifluridine/Tipiracil
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer
- Plain-language title
- Tests telisotuzumab adizutecan with bevacizumab in colorectal cancer that stopped respondingGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 2026
- Record updated
- 19 October 2026